New factors which regulate renal vitamin D1 alfa hydroxylase;Nuevos factores que intervienen en la regulación de la 1 alfa hidroxilasa renal de la vitamina D

Nefrologia

Volumn 25, Issue 6, 2005, Pages 602-607

  Negri, Armando Luis ^a,b   Fradinger, E ^a  

^a UNIVERSIDAD DEL SALVADOR   (Argentina)

^b Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID MONOOXYGENASE; VITAMIN D 1 ALPHA HYDROXYLASE; VITAMIN D 1-ALPHA HYDROXYLASE;

ANIMAL; HUMAN; KIDNEY; PHYSIOLOGY; REVIEW;

ANIMALS; HUMANS; KIDNEY; STEROID HYDROXYLASES;

EID: 33646555779     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Kumar R: Metabolism of 1,25-dihydroxy vitamin D3. Physiol Rev 64: 478-504, 1984.
2. Breslau NA: Normal and abnormal regulation of 1,25(OH)2 synthesis. Am J Med Sci 296: 417-425, 1988.
3. Nebert DW and González FJ: P450 genes: structure, evolution and regulation. Annu Rev Biochem 56: 945-993, 1987.
4. Black SD and Coon MJ P-450 cytochromes: Structure and function. Adv Enzymo Relat Areas Mol Biol 60: 35-87, 1987.
5. Auchus RJ, Lee TC, Miller WL: Cytochrome B5 augments the 17,20 lyase activity of human P450c17 without direct electron transfer. J Biol Chem 273: 3158-3165, 1998.
6. Sakaki T, Kagawa N, Yamamoto K, and Inouyre K: Metabolism of vitamin D3 by cytochomes P450 Front Biosci 10: 119-34, 2005.
7. St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH: The 25-hydroxy-vitamin D 1 alfa -hiydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR)) disease locus. J Bone Mineral Res 12: 1552-1559, 1997.
8. Shinki T, Shimada H, Wakino S, Anazawa H, Hayashi M, Saruta T, DeLuca HF, Suda T: Cloning and expression of rat 25-hydroxivitamin D3-1 alfa hydroxylase cDNA Proc Natl Acad Sci U.S.A. 94: 12920-12925, 1997.
9. Henry HL and Luntao EM: Interactions between intracellular signals involved in the regulation of 25-hydroxyvitamin D3 metabolism. Endocrinology 124: 2228-2234, 1989.
10. Brenza H, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, Suda T, DeLuca HF: Parathyroid hormone activation of the 25-hydroxivitamin D-1 alfa-hydroxilase gene promoter. Proc Natl Acad Sci USA 95 (4): 1387-1391, 1998.
11. Murayama A, Takeyama K, Kitanaka S, Kodera Y, Kawaguchi Y, Hosoya T, Kato S: Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology 140 (5): 2224-31, 1999.
12. Brenza HL, DeLuca HF: Regulation of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3. Arch Biochem Biophys 381 (1): 143-52, 2000.
13. Kong XF, Zhu XH, Pei YL, Jackson DM, Hollick MF: Molecular cloning, characterization and promoter analysis of human 25-hydroxyvitamin D3-1 alfa-hydroxylase gene. PNAS 96: 6988-6993, 1999.
14. Shinki T, Ueno Y, DeLuca HF, Suda T: calcitonin is a mayor regulator for the expression of renal 25-hydroxyvitamin D3 1 alfa-hydroxylase gene in normocalcemic rats. PNAS 96: 8253-8258, 1999.
15. Bland R, Walker E, Hughes SV, Stewart PM, Hewison M: Constitutive expression of 25-hydroxyvitamin D 1-alfa-hydroxylase in transformed human proximal tubular cell line: evidence of direct regulation of vitamin D metabolism by calcium. Endocrinology 140: 2027-2034, 1999.
16. Zhang MY, Wang X, Wang JT, Compagnone NA, Nellon SH, Olson JL, Tenenhouse HS, Miller WL, Portale AA: Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1alpha-hydroxylase gene expression in the proximal renal tubule. Endocrinology 143 (2): 587-95, 2002.
17. Econs MJ and McEnery PT: Autosomal dominant hypophosphtemic rickets/osteomalacia: clinical characterization of a novel renal phosphate wasting disorder. J Clin Endocrinol Metab 82: 674-681, 1997.
18. The ADHR Consortium: Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348, 2000.
19. Econs MJ, McEnery PT, Lennon Fand Spencer MC: Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 100: 2653-2657, 1997.
20. Powers CJ, McLeskey SW, and Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165-197, 2000.
21. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, and Shamashita T: Cloning and characterization of FGF23 as a causative factor of tumor induced osteomalacia. Proc Natl Acad Sci USA 98: 6500-6505, 2001.
22. White KE, Carn G, Lorenz-Depiereux B y cols.: ADHR mutations stabilize FGF23. Kidney Int 60: 2079-2086, 2002.
23. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, and Shamashita T: Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic clevage and causes hypophosphatemia in vivo. Endocrinology 143: 3179-3182, 2002.
24. Bai XY, Miao D, Goltzman d, Karpalis AC: The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic clevage and enhances in vitro biological potency. J Biol Chem 278 (11): 9843-9, 2003.
25. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Futyita Y, Fukumoto S, Yamashita T: FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314 (2): 409-14, 2004.
26. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fuyita T, Fukumoto S, Tomisuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 (4): 561-8, 2004.
27. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima Y, Mutation of the klotho gene leads to a syndrome resembling ageing. Nature (London) 390: 45-51, 1997.
28. Tohyama O, Imura A, Iwano A, Freund JN, Henrissat B, Fujimori T, Nabeshima Y: Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 279 (11): 9777-84, 2004.
29. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y: Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 242: 626-630, 1998.
30. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y: Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565 (1-3): 143-7, 2004.
31. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y., Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17 (12): 2393-403, 2003.
32. Morishita K, Shirai A, Kubota M, Katakura Y, Nabeshima Y, Takeshige K, Kamiyal T, The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 131: 3182-3188, 2001.